Quick answer
What is Teriparatide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Teriparatide is a peptide, grouped on this site under Endocrine and immune signalling peptides, and the 12 research records kept here are 1 from a study in rats or mice, 9 from trials in people and 2 that do not state what kind of study it is.
The literature search returned 3,057 records. This site keeps 12 of them, which is 0.39 per cent of what came back.
What it is
This site puts it in the Endocrine and immune signalling peptides group.
A parathyroid hormone receptor agonist; the retrieved records report anabolic effects on bone remodelling that differ in direction from bisphosphonates.[1, 2]
Stated in the titles of the cited 2005 Archives of Internal Medicine and 2003 Journal of Bone and Mineral Research papers.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 9 of 12 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 3,045 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Archives of internal medicine (2005). pmid:16087825
- Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2003). pmid:14606504